Phase I Study of MEK Inhibitor Selumetinib in Combination With Azacitidine in Patients With Higher Risk Chronic Myeloid Neoplasia: MDS, MDS/MPNs, and Myelofibrosis
Phase of Trial: Phase I
Latest Information Update: 23 Oct 2018
Price : $35 *
At a glance
- Drugs Azacitidine (Primary) ; Selumetinib (Primary)
- Indications Myelofibrosis; Myeloid leukaemia
- Focus Adverse reactions
- 12 Oct 2018 Planned End Date changed from 1 Aug 2020 to 4 Sep 2023.
- 12 Oct 2018 Planned primary completion date changed from 1 Jun 2020 to 4 Sep 2021.
- 12 Oct 2018 Status changed from not yet recruiting to recruiting.